1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018, 68(6):394-424.
2. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY et al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanc ed gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014, 15(11):1224-1235.
3. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1 D2 trial. Lancet Oncol 2010, 11(5):439-449.
4. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS et al: Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016, 14(10):1286-1312.
5. Kim D, Kim DH: Epigenome-Based Precision Medicine in Lung Cancer. Methods Mol Biol 2018, 1856:57-85.
6. Considine B, Petrylak DP: Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care-Part 1: The Non-Androgen-T argetable Pathways in Castration-Resistant Prostate Cancer. Oncology (Williston Park) 2019, 33(3):113-118.
7. Kaidar-Person O, Gil Z, Billan S: Precision medicine in head and neck cancer. Drug Resist Updat 2018, 40:13-16.
8. Mitamura T, Dong P, Ihira K, Kudo M, Watari H: Molecular-targeted therapies and precision medicine for endometrial cancer. Jpn J Clin Oncol 2019, 49(2):108-120.
9. Nasrazadani A, Thomas RA, Oesterreich S, Lee AV: Precision Medicine in Hormone Receptor-Positive Breast Cancer. Front Oncol 2018, 8:144.
10. Zeng J, Cai X, Hao X, Huang F, He Z, Sun H, Lu Y, Lei J, Zeng W, Liu Y et al: LncRNA FUNDC2P4 down-regulation promotes epithelial-mesenchymal transition by reducing E-cadherin exp ression in residual hepatocellular carcinoma after insufficient radiofrequency ablation. Int J Hyperthermia 2018, 34(6):802-811.
11. Zhong X, Long Z, Wu S, Xiao M, Hu W: LncRNA-SNHG7 regulates proliferation, apoptosis and invasion of bladder cancer cells assurance guidel ines. J buon 2018, 23(3):776-781.
12. Shi X, Zhao Y, He R, Zhou M, Pan S, Yu S, Xie Y, Li X, Wang M, Guo X et al: Three-lncRNA signature is a potential prognostic biomarker for pancreatic adenocarcinoma. Oncotarget 2018, 9(36):24248-24259.
13. Huang Y, Xiang B, Liu Y, Wang Y, Kan H: LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis. Cancer Lett 2018, 437:56-66.
14. Yu C, Hao X, Zhang S, Hu W, Li J, Sun J, Zheng M: Characterization of the prognostic values of the NDRG family in gastric cancer. Therap Adv Gastroenterol 2019, 12:1756284819858507.
15. Yu C, Zhang Y: Characterization of the prognostic values of CXCR family in gastric cancer. Cytokine 2019, 123:154785.
16. Jiang B, Sun Q, Tong Y, Wang Y, Ma H, Xia X, Zhou Y, Zhang X, Gao F, Shu P: An immune-related gene signature predicts prognosis of gastric cancer. Medicine 2019, 98(27):e16273.
17. Yang W, Lai Z, Li Y, Mu J, Yang M, Xie J, Xu J: Immune signature profiling identified prognostic factors for gastric cancer. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2019, 31(3):463-470.
18. Cheng C, Wang Q, Zhu M, Liu K, Zhang Z: Integrated analysis reveals potential long non-coding RNA biomarkers and their potential biological f unctions for disease free survival in gastric cancer patients. Cancer Cell Int 2019, 19:123.
19. Zhang Z, Ouyang Y, Huang Y, Wang P, Li J, He T, Liu Q: Comprehensive bioinformatics analysis reveals potential lncRNA biomarkers for overall survival in pat ients with hepatocellular carcinoma: an on-line individual risk calculator based on TCGA cohort. Cancer Cell Int 2019, 19:174.
20. Zhang L, Chen S, Wang B, Su Y, Li S, Liu G, Zhang X: An eight-long noncoding RNA expression signature for colorectal cancer patients' prognosis. Journal of cellular biochemistry 2019, 120(4):5636-5643.
21. Xu H, Gu X, Tadesse MG, Balasubramanian R: A Modified Random Survival Forests Algorithm for High Dimensional Predictors and Self-Reported Outcomes. Journal of computational and graphical statistics : a joint publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America 2018, 27(4):763-772.
22. Nasejje JB, Mwambi H: Application of random survival forests in understanding the determinants of under-five child mortality in Uganda in the presence of covariates that satisfy the proportional and non-proportional hazards assumption. BMC research notes 2017, 10(1):459.
23. Bisaso KR, Karungi SA, Kiragga A, Mukonzo JK, Castelnuovo B: A comparative study of logistic regression based machine learning techniques for prediction of early virological suppression in antiretroviral initiating HIV patients. BMC medical informatics and decision making 2018, 18(1):77.
24. LD F, DY L: Time-dependent covariates in the Cox proportional-hazards regression model. Annual review of public health 1999, 20(undefined):145-157.
25. Ruyssinck J, van der Herten J, Houthooft R, Ongenae F, Couckuyt I, Gadeyne B, Colpaert K, Decruyenaere J, De Turck F, Dhaene T: Random Survival Forests for Predicting the Bed Occupancy in the Intensive Care Unit. Computational and mathematical methods in medicine 2016, 2016:7087053.
26. Halme HL, Parkkonen L: Across-subject offline decoding of motor imagery from MEG and EEG. Scientific reports 2018, 8(1):10087.
27. Robinson MD, McCarthy DJ, Smyth GK: edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26(1):139-140.
28. Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontius J, Berger P, Desborough V, Smith T, Campbell J et al: ImmPort: disseminating data to the public for the future of immunology. Immunol Res 2014, 58(2-3):234-239.
29. Mei S, Meyer CA, Zheng R, Qin Q, Wu Q, Jiang P, Li B, Shi X, Wang B, Fan J et al: Cistrome Cancer: A Web Resource for Integrative Gene Regulation Modeling in Cancer. Cancer Res 2017, 77(21):e19-e22.
30. Alaeddini A, Hong SH: A Multi-way Multi-task Learning Approach for Multinomial Logistic Regression*. An Application in Joint Prediction of Appointment Miss-opportunities across Multiple Clinics. Methods of information in medicine 2017, 56(4):294-307.
31. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003, 13(11):2498-2504.
32. Huang YW, Luo J, Weng YI, Mutch DG, Goodfellow PJ, Miller DS, Huang TH: Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endo metrial carcinomas. Gynecol Oncol 2010, 117(2):239-247.
33. de Carvalho DD, Sadok A, Bourgarel-Rey V, Gattacceca F, Penel C, Lehmann M, Kovacic H: Nox1 downstream of 12-lipoxygenase controls cell proliferation but not cell spreading of colon cancer cells. Int J Cancer 2008, 122(8):1757-1764.
34. Stalin J, Garrido-Urbani S, Heitz F, Szyndralewiez C, Jemelin S, Coquoz O, Ruegg C, Imhof BA: Inhibition of host NOX1 blocks tumor growth and enhances checkpoint inhibitor-based immunotherapy. 2019, 2(4).
35. DeDiego ML, Martinez-Sobrido L, Topham DJ: NOVEL FUNCTIONS OF THE INTERFERON-INDUCED PROTEIN 44-LIKE (IFI44L) AS A FEEDBACK REGULATOR OF HOST AN TIVIRAL RESPONSES. J Virol 2019.
36. Yang JW, Yang DY, Lu FG, Li CH, Chen H, Xie N, Zhao X: GPC3 fused to an alpha epitope of HBsAg acts as an immune target against hepatocellular carcinoma ass ociated with hepatitis B virus. Hepatobiliary Pancreat Dis Int 2011, 10(2):164-170.
37. Wang Y, Liu J, Pan H, Xing J, Wu X, Li Q, Wang Z: A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity. J Vis Exp 2018(137).
38. Sun T, Ferrero RL, Girardin SE, Gommerman JL, Philpott DJ: NLRC5 deficiency has a moderate impact on immunodominant CD8+ T-cell responses during rotavirus infec tion of adult mice. Immunol Cell Biol 2019, 97(6):552-562.
39. Wang Q, Ding H, He Y, Li X, Cheng Y, Xu Q, Yang Y, Liao G, Meng X, Huang C et al: NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/¦Â-catenin signalling pathway in clear cell renal cell carcinoma. Cancer Lett 2019, 444:9-19.
40. Li J, Liao Y, Ding T, Wang B, Yu X, Chu Y, Xu J, Zheng L: Tumor-infiltrating macrophages express interleukin-25 and predict a favorable prognosis in patients w ith gastric cancer after radical resection. Oncotarget 2016, 7(10):11083-11093.
41. Shen Z, Kauttu T, Cao J, Sepp?nen H, Vainionp S, Ye Y, Wang S, Mustonen H, Puolakkainen P: Macrophage coculture enhanced invasion of gastric cancer cells via TGF-¦Â and BMP pathways. Scand J Gastroenterol 2013, 48(4):466-472.
42. Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, Kim WH: Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer 2008, 99(10):1704-1711.
43. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003, 9(12):4404-4408.
44. Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM et al: Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated im mune stroma. Gut 2017, 66(5):794-801.
45. Carlson LM, De Geer A, Sveinbj?rnsson B, Orrego A, Martinsson T, Kogner P, Levitskaya J: The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes. Oncoimmunology 2013, 2(3):e23618.
46. Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, Jetten AM, Khoury SJ, Fuhlbrigge RC, Kuchroo VK et al: Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012, 18(8):1248-1253.
47. Schuster S, Hurrell B, Tacchini-Cottier F: Crosstalk between neutrophils and dendritic cells: a context-dependent process. J Leukoc Biol 2013, 94(4):671-675.
48. Okita Y, Ohira M, Tanaka H, Tokumoto M, Go Y, Sakurai K, Toyokawa T, Kubo N, Muguruma K, Sawada T et al: Alteration of CD4 T cell subsets in metastatic lymph nodes of human gastric cancer. Oncol Rep 2015, 34(2):639-647.
49. Ananiev J, Gulubova MV, Manolova IM: Prognostic significance of CD83 positive tumor-infiltrating dendritic cells and expression of TGF-bet a 1 in human gastric cancer. Hepatogastroenterology 2011, 58(110-111):1834-1840.
50. Wang TT, Zhao YL, Peng LS, Chen N, Chen W, Lv YP, Mao FY, Zhang JY, Cheng P, Teng YS et al: Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression thro ugh GM-CSF-PD-L1 pathway. Gut 2017, 66(11):1900-1911.